What is NDC 0002-1717?

0002-1717 is the product NDC for Inluriyo (imlunestrant), Imlunestrant 200 mg/1 tablet, film coated, listed with the FDA by Eli Lilly and Company. It has 3 package NDCs, shown above in 10- and 11-digit form.

Eli Lilly and Company, NDC labeler code 0002. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Inluriyo?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Inluriyo NDC 0002-1717 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)0002-1717Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00002-1717Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
0002-1717-28	00002171728	28 TABLET, FILM COATED in 1 BOTTLE (0002-1717-28)Marketed from Oct 16, 2025
0002-1717-56	00002171756	56 TABLET, FILM COATED in 1 BOTTLE (0002-1717-56)Marketed from Oct 15, 2025
0002-1717-61	00002171761	56 TABLET, FILM COATED in 1 BOTTLE (0002-1717-61)Marketed from Nov 13, 2025 · Sample package

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Inluriyo
Generic name (nonproprietary): imlunestrant
Active ingredients: Imlunestrant — 200 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Eli Lilly and CompanyNDC labeler code 0002
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 218881
Marketing start: Sep 25, 2025
Listing expires: Dec 31, 2027
Other FDA classes: Breast Cancer Resistance Protein Inhibitors (Mechanism)Estrogen Receptor Antagonists (Mechanism)P-Glycoprotein Inhibitors (Mechanism)
Identifiers: Product ID 0002-1717_d4c7332d-4da7-4d70-8813-4cecd53fff2aSPL ID d4c7332d-4da7-4d70-8813-4cecd53fff2aSPL set ID 5bc172e4-e8a2-441a-be52-279a7f890196RxCUI 2725917, 2725923UNII 9CXQ3PF69U
Pharmacologic class: Estrogen Receptor Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400002171728 followed by a unit qualifier and the quantity

Package 00002-1717-28. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 4, 2026.

Indications (excerpt from the label)

INLURIYO is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 ( ESR1 )-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. INLURIYO TM is an estrogen receptor antagonist indicated for: treatment of adults with ER-positive, HER2-negative, ESR1 -mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 0002-1717

What is NDC 0002-1717?: 0002-1717 is the product NDC for Inluriyo (imlunestrant), Imlunestrant 200 mg/1 tablet, film coated, listed with the FDA by Eli Lilly and Company. It has 3 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Inluriyo (Imlunestrant).
What is the active ingredient?: Imlunestrant.
Who is the labeler?: Eli Lilly and Company, NDC labeler code 0002. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Inluriyo?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Inluriyo (Imlunestrant) NDC 0002-1717